Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed

VERTEX PHARMACEUTICALS INC / MA

2025-Q2 EPS reported $6.48 vs consensus $4.37 ▲ beat (+48.3%)

Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B
Reiterated FY25 revenue guidance $11.85-$12.0B; combined R&D/SG&A guidance unchanged
CSO David Altshuler to retire Aug 1, 2026; Mark Bunnage becomes CSO effective Feb 1, 2026 as planned transition
VX-993 Phase 2 acute pain study missed primary endpoint; Vertex not advancing it as monotherapy
CASGEVY: ~115 patients had first cell collection, 29 infused; JOURNAVX: >110,000 prescriptions filled

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.